Somatic cell nuclear transfer technology ban in Lott cloning bill is objectionable to PhRMA.
SOMATIC CELL NUCLEAR TRANSFER TECHNOLOGY BAN OBJECTIONABLE TO PhRMA, Pharmaceutical Research & Manufacturers of America Exec VP Judith Bello indicated during a Capitol Hill press conference Feb. 6. Bello cited the specific ban on that technology as a problem with Senate legislation addressing human cloning. "Any ban on any particular technology" would set a "terrible adverse precedent," Bello said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth